We evaluated the effectiveness of latanoprost (Xalatan) monotherapy in primary open angle glaucoma (POAG). Latanoprost is a prostaglandin analogue, the pure 15(R) epimer of 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2alpha-isopropyl ester. As a prodrug it is being activated by enzymatic hydrolysis in the cornea after which it becomes active acid of latanoprost. Latanoprost is lowering the intraocular pressure (IOP) by increasing the uveoscleral outflow. In this study, latanoprost was used once daily as monotherapy what offers much better compliance for the patients than other combinations of drugs, preserving good IOP control. Based on the significant reduction of the IOP, measured on the day 60 of the trial (mean change in IOP was -5.1 mmHg, with 95% confidence interval in range from -5.6 to -4.5), it is concluded that use of latanoprost is advisable when calculating better IOP control, few side-effects and reductions in costs of potential surgical procedures.
Tamer C, Oksüz H. Tamer C, et al. Ophthalmic Res. 2007;39(1):24-31. doi: 10.1159/000097903. Epub 2006 Dec 11. Ophthalmic Res. 2007. PMID: 17164574 Clinical Trial.
Mansouri K, Orguel S, Mermoud A, Haefliger I, Flammer J, Ravinet E, Shaarawy T. Mansouri K, et al. Br J Ophthalmol. 2008 Mar;92(3):332-6. doi: 10.1136/bjo.2007.123042. Epub 2008 Jan 22. Br J Ophthalmol. 2008. PMID: 18211927 Clinical Trial.
Maruyama K, Shirato S. Maruyama K, et al. J Glaucoma. 2006 Aug;15(4):341-5. doi: 10.1097/01.ijg.0000212240.11219.49. J Glaucoma. 2006. PMID: 16865013 Clinical Trial.
Holmstrom S, Buchholz P, Walt J, Wickstrøm J, Aagren M. Holmstrom S, et al. Curr Med Res Opin. 2005 Nov;21(11):1875-83. doi: 10.1185/030079905X65600. Curr Med Res Opin. 2005. PMID: 16307709 Review.
Digiuni M, Fogagnolo P, Rossetti L. Digiuni M, et al. Expert Opin Pharmacother. 2012 Apr;13(5):723-45. doi: 10.1517/14656566.2012.662219. Epub 2012 Feb 21. Expert Opin Pharmacother. 2012. PMID: 22348427 Review.